Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(capecitabine)
6,571 results
  • Permanent lesion to the corticospinal tract after therapy with capecitabine. [Journal Article]
    BMJ Case Rep 2019; 12(9)Wagner-Altendorf TA, Heldmann M, … Münte TF
  • Capecitabine is an oral fluoropyrimidine used to treat solid tumours such as colorectal and breast cancer. A rare but severe side effect is capecitabine-induced leukoencephalopathy, including bilateral lesion to the corticospinal tract. However, neurological symptoms due to capecitabine treatment are usually reported to be reversible after discontinuation of capecitabine. Here, we present the cas…
  • Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient. [Case Reports]
    Case Rep Genet 2019; 2019:5150725Bukhari N, Azam F, … Zahrani M
  • Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report a 65-year-old female with rectal adenocarcinoma who experienced severe toxicities secondary to standard dose 5-FU based chemotherapy. She was found to be heterozygous for rs371313778, c.2434G>A. This finding prompted restarting 5-FU at 50% dose reduction wit…
  • Innumerable Squamous Cell Carcinomas in Vietnam War Veteran Exposed to Chemical Defoliants. [Case Reports]
    J Clin Aesthet Dermatol 2019; 12(8):47-50Desimone J, Beatson M
  • CONCLUSIONS: Management of patients with overwhelming numbers of SCCs is extremely challenging. Combination topical and/or intralesional 5-fluorouracil and oral capecitabine may be considered as part of the management approach when mechanical destruction and surgery alone are not feasible. Multidisciplinary care coordinated between the surgeon, dermatologic oncologist, medical oncologist, and radiation oncologist is essential for providing comprehensive treatment and deploying preventative strategies in this population at high risk for metastatic SCC formation.
  • Pulsed reduced dose rate for re-irradiation of recurrent breast cancer. [Journal Article]
    Pract Radiat Oncol 2019Burr AR, Robins HI, … Howard SP
  • CONCLUSIONS: PRDR radiation therapy with capecitabine were well tolerated and effective method for treating patients with recurrent breast cancer. Prospective studies are necessary to compare side effects and efficacy with conventional dose rate re-irradiation, as well as, to evaluate the potential role for capecitabine in the recurrent setting.
New Search Next